Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05828303 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Start date: June 28, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.

NCT ID: NCT05824975 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors

Start date: May 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.

NCT ID: NCT05821777 Recruiting - Clinical trials for Advanced Solid Tumor

A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors

Start date: March 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess safety, tolerability, and preliminary activity of LB101 monotherapy in participants with advanced solid tumors.

NCT ID: NCT05819684 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Start date: April 18, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

NCT ID: NCT05805956 Recruiting - Clinical trials for Advanced Solid Tumor

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Start date: February 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors

NCT ID: NCT05798611 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ART0380 in Patients With Biologically Selected Solid Tumors

ARTIST
Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

NCT ID: NCT05794477 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Start date: April 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.

NCT ID: NCT05790447 Recruiting - Clinical trials for Advanced Solid Tumor

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Start date: April 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of precise thymalfasin-regulated therapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF for treatment of advanced refractory solid tumors.

NCT ID: NCT05789602 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of BPI-460372 in Advanced Solid Tumor Patients

Start date: April 24, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.

NCT ID: NCT05785741 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Start date: April 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.